Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Meduvo LLC, a compounding pharmacy. Meduvo currently operates from a 2,000-square-foot facility in La Verne, California, where it compounds and dispenses non-sterile medications. The acquisition expands the company’s already wide network to 34 jurisdictions in the United States and establishes a strategic West Coast operational hub (https://ibn.fm/UyyO2).
The recent acquisition aligns with Earth Science Tech’s focus on scaling its business by expanding its geographic footprint, advancing its popular telehealth and pharmacy fulfillment platforms. This focus is part of the company’s strategy to integrate the patient experience, from telemedicine to pharmacy to fulfilment, into a unified system to serve patients more effectively while building a stronger and more profitable operation (https://ibn.fm/GJNhV).
“Looking ahead, our core focus remains on optimizing the operational frameworks of our holdings to support scalable, sustainable expansion,” said Giorgio R. Saumat, CEO and Chairman of the Board, in his 2026 annual letter to shareholders (https://ibn.fm/MpgTz). “I expect every company under the ETST umbrella to expand its geographic footprint this year, and we will pursue acquisitions and/or partnerships where they help us meet that goal.”
Even with the acquisition complete, Earth Science Tech is still targeting further expansion and operational optimization: the company plans to capture broader market share and unlock long-term, high-margin revenue by initiating upgrades at Meduvo’s La Verne facility. The upgrades will ensure the facility meets strict sterility requirements, with ETST’s management targeting full regulatory certification for sterile compounding by the end of 2028.
Earth Science Tech operates other compounding pharmacies through its specialized subsidiaries, Miami-based RxCompoundStore.com LLC (“RxCS”) and Abilene, Texas-based Mister Meds LLC. RxCS provides sterile and non-sterile medications, while Mister Meds is licensed to handle hazardous drugs and compound sterile medication.
The addition of Meduvo into this existing network of compounding pharmacies means that the company can dispense medication across Alabama, Arizona, California, Colorado, Delaware, Florida, Georgia, Idaho, Illinois, Indiana, Iowa, Maine, Maryland, Massachusetts, Minnesota, Mississippi, Missouri, Nevada, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Puerto Rico, Rhode Island, South Carolina, South Dakota, Texas, Utah, Vermont, Virginia, Wisconsin, and Wyoming.
For more information, visit the company’s website at www.EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://ibn.fm/ETST
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the…
Glioblastoma is very difficult to treat because it quickly adapts and evolves to become resistant…
Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving…
Researchers from the University of Manchester in the UK have found that a small group…
Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with…
Dozens of global drugmakers are ramping up their investments in the United States in a bid to…